Pay in 4 interest-free payments of $6.54 Learn more
Ships within 48 hours · Estimated delivery Oct 7 - Oct 12
In 2023, Pfizer published research papers successively, reporting the results of randomized clinical trials on the efficacy and safety of PF-06882961 for blood sugar control in patients with type 2 diabetes, the safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06882961 in Japanese adults with type 2 diabetes from a phase 1 clinical trial, and the results of a 12-week randomized, placebo-controlled, dose-escalation phase 2 trial on the tolerability, safety, and pharmacodynamics of PF-06882961 for the treatment of type 2 diabetes
These candidates demonstrate clinical differentiation and innovation, moving beyond traditional biosimilar or fast-follower strategies
Avoid snacks that deliver mostly carbohydrates or fat without meaningful protein
Diabetes 69(4):542549
Diabetol Metab Syndr 17(1):68 Nauck MA, Quast DR (2021) Cardiovascular safety and benefits of semaglutide in patients with type 2 diabetes: findings from SUSTAIN 6 and PIONEER 6
US$ 24.11
US$ 25.63
US$ 20.24
US$ 21.97
US$ 25.17
US$ 24.50
US$ 23.05
US$ 27.85
US$ 27.04
US$ 21.00
US$ 26.13
